12:00 AM
Sep 08, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Fluidosomes Tobramycin: Phase IIa started

Axentis began an international Phase IIa trial to evaluate 2 dosages of ARB-CF0223 in 24 patients with CF. The company licensed the...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >